Cargando…
Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors
BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 1...
Autores principales: | Guan, Wei, Li, Songlin, Zhang, Zhimin, Xiao, He, He, Juan, Li, Jian, He, Xuan, Luo, Jia, Liu, Yun, Lei, Lin, Ma, Jungang, Chen, Lizhao, Chen, Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575130/ https://www.ncbi.nlm.nih.gov/pubmed/36073321 http://dx.doi.org/10.1111/1759-7714.14628 |
Ejemplares similares
-
Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors
por: Li, Songlin, et al.
Publicado: (2019) -
Epigenetics of Thymic Epithelial Tumors
por: Nicolì, Vanessa, et al.
Publicado: (2023) -
Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations
por: Psilopatis, Iason, et al.
Publicado: (2022) -
Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019) -
STAT3 expression correlates with prognosis of thymic epithelial tumors
por: Li, Chao, et al.
Publicado: (2013)